In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

Berry softball coach Darrell Thomas leads team into North Regional next week while undergoing chemotherapy treatments.

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...

Heidi Shupe has a myriad of medals proudly displayed in her home. But 20 years ago, her life looked a lot different.

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March ...

Researchers sought to assess the access to CAR-T therapy for patients within community-based and transplant cell therapy networks.